Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resistant or Refractory Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Early research (Phase 1)Temporarily pausedNCT04840589
What this trial is testing

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Platinum-Resistant Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 66
Early research (Phase 1)Study completedNCT00011414
What this trial is testing

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

Who this might be right for
Wilms' TumorSarcomaAdenaocortical Carcinoma+2 more
National Cancer Institute (NCI) 29
Early research (Phase 1)Ended earlyNCT04541225
What this trial is testing

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Who this might be right for
GliomaGlioma, MalignantGlioma, Mixed+21 more
Nuvation Bio Inc. 74
Early research (Phase 1)Study completedNCT04686383
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Who this might be right for
Resistant or Refractory Solid Tumors
Calgent Biotechnology Co., Ltd 17